Hemophilia A is caused by a mutation in the F8 (factor VIII) gene, while hemophilia B is due to a mutation in the F9 (factor IX) gene. In patients with these conditions, the activities of factor VIII or factor IX in the blood plasma are significantly reduced, leading to spontaneous or post-traumatic bleeding. The global incidence of hemophilia A and B is estimated to be approximately 1 in 5000 and 1 in 30,000 newborns, respectively. Consequently, it is anticipated that the global number of individuals with hemophilia may exceed 1.1 million.
● Genetically Engineered Hemophilia Mouse Models
Strain No.
|
Strain Name | Strain Type | Description |
---|---|---|---|
T013686 | F9-KO | Knockout | F9-KO hemizygous male and homozygous female mice display no F9 expression and impaired blood coagulation capacity. |
T004727 | B6-F8-KO | Knockout | F8-KO hemizygous male and homozygous female mice display reduced FVIII activity (~3% compared to wildtype) and impaired blood coagulation, which can be partially attenuated by administration of recombinant FVIII |